The asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS): Opportunities and challenges

Current Opinion in Pulmonary Medicine

Volumn 21, Issue 1, 2015, Pages 74-79

  Barrecheguren, Miriam ^a   Esquinas, Cristina ^a   Miravitlles, Marc ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

ACOS; Asthma; Asthma COPD overlap syndrome; COPD; Diagnosis

Indexed keywords

BRONCHODILATING AGENT; CARBON MONOXIDE; CORTICOSTEROID; MYELOPEROXIDASE; NITRIC OXIDE; SODIUM CHLORIDE; SURFACTANT PROTEIN A; TIOTROPIUM BROMIDE; G PROTEIN COUPLED RECEPTOR; GPR65 PROTEIN, HUMAN;

AIRWAY OBSTRUCTION; ASTHMA; ASTHMA CHRONIC OBSTRUCTIVE PULMONARY DISEASE OVERLAP SYNDROME; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL PRACTICE; COMORBIDITY; COUGHING; DYSPNEA; EMPHYSEMA; EOSINOPHILIA; FINANCIAL MANAGEMENT; HEALTH PRACTITIONER; HUMAN; LUNG DISEASE; LUNG FUNCTION; PHENOTYPE; PNEUMONIA; PRACTICE GUIDELINE; RESPIRATORY TRACT INFLAMMATION; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SPUTUM; WHEEZING; DISEASE COURSE; DRUG EFFECTS; EOSINOPHIL; GENETICS; IMMUNOLOGY; INFLAMMATION; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION TEST; PATHOPHYSIOLOGY; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ASTHMA; DISEASE PROGRESSION; EOSINOPHILS; HUMANS; INFLAMMATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, G-PROTEIN-COUPLED; RESPIRATORY FUNCTION TESTS; SPUTUM;

EID: 84918514503     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0000000000000118     Document Type: Review

References (45)

1. O'Donnell DE, Aaron S, Bourbeau J, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease 2007 update. Can Respir J 2007; 14 (Suppl B):5B-32B.
2. Disantostefano RL, Li H, Rubin DB, Stempel DA. Which patients with chronic obstructive pulmonary disease benefit from the addition of an inhaled corticosteroid to their bronchodilator? A cluster analysis. Br Med J Open 2013; 3:e001838.
3. Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet 2012; 379:1341-1351.
4. Miravitlles M, Calle M, Soler-Cataluña JJ. Clinical phenotypes of COPD. Identification, definition and implications for guidelines. Arch Bronconeumol 2012; 48:86-98.
5. Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: The future of COPD. Am J Respir Crit Care Med 2010; 182:598-604.
6. Gibson PG, Simpson JL. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax 2009; 64:728-735.
7. Louie S, Zeki AA, Schivo M, et al. The asthma-chronic obstructive pulmonary disease overlap syndrome: pharmacotherapeutic considerations. Expert Rev Clin Pharmacol 2013; 6:197-219.
8. GINA-GOLD. Diagnosis of disease of chronic airflow limitation: Asthma, COPD and asthma-COPD overlap syndrome (ACOS). http://www.goldcopd.org/asthma-copd-overlap.html. [Accessed 5 August 2014].
9. Lee HY, Kang JY, Yoon HK, et al. Clinical characteristics of asthma combined with COPD feature. Yonsei Med J 2014; 55:980-986.
10. Piras B, Miravitlles M. The overlap phenotype: The (missing) link between asthma and COPD. Multidiscip Respir Med 2012; 7:8.
11. Perret JL, Dharmage SC, Matheson MC, et al. The interplay between the effects of lifetime asthma, smoking, and atopy on fixed airflow obstruction in middle age. Am J Respir Crit Care Med 2013; 187:42-48.
12. Miravitlles M, Andreu I, Romero Y, et al. Difficulties in differential diagnosis of COPD and asthma in primary care. Br J Gen Pract 2012; 62:e68-e75.
13. Kitaguchi Y, Komatsu Y, Fujimoto K, et al. Sputum eosinophilia can predict responsiveness to inhaled corticosteroid treatment in patients with overlap syndrome of COPD and asthma. Int J Chron Obstruct Pulmon Dis 2012; 7:283-289.
14. Nakawah MO, Hawkins C, Barbandi F. Asthma, chronic obstructive pulmonary disease (COPD), and the overlap syndrome. J Am Board Fam Med 2014; 26:470-477.
15. Papaiwannou A, Zarogoulidis P, Porpodis K, et al. Asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS): current literature review. J Thorac Dis 2014; 6 (Suppl 1):S146-S151.
16. Fabbri LM, Romagnoli M, Corbetta L, et al. Differences in airway inflammation in patients with chronic fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 167:418-424.
17. Papi A, Romagnoli M, Baraldo S, et al. Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 162:1773-1777.
18. Chou KT, Su KC, Huang SF, et al. Exhaled nitric oxide predicts eosinophilic airway inflammation in COPD. Lung 2014; 192:499-504.
19. Iwamoto H, Gao J, Koskela J, et al. Differences in plasma and sputum biomarkers between COPD and COPD-asthma overlap. Eur Respir J 2014; 43:421-429.
20. Hardin M, Cho M, McDonald M-L, et al. The clinical and genetic features of COPD-asthma overlap syndrome. Eur Respir J 2014; 44:341-350.
21. Hardin M, Silverman EK, Barr RG, et al. The clinical features of overlap between COPD and asthma. Respir Res 2011; 12:127.
22. Miravitlles M, Soriano JB, Ancochea J, et al. Characterisation of the overlap COPD-asthma phenotype. Focus on physical activity and health status. Respir Med 2013; 107:1053-1060.
23. Menezes AM, de Oca MM, Pérez-Padilla R, et al. Increased risk of exacerbation and hospitalization in subjects with an overlap phenotype COPD asthma. Chest 2014; 145:297-304.
24. Chung JW, Kong KA, Lee JH, et al. Characteristics and self-rated health of overlap syndrome. Int J Chron Obst Pulm Dis 2014; 9:795-804.
25. Kauppi P, Kupiainen H, Lindqvist A, et al. Overlap syndrome of asthma and COPD predicts low quality of life. J Asthma 2011; 48:279-285.
26. Miravitlles M, Huerta A, Fernández-Villar JA, et al. Generic utilities in chronic obstructive pulmonary disease patients stratified according to different staging systems. Health Qual Life Outcomes 2014; 12:120.
27. Shaya FT, Dongyi D, Akazawa MO, et al. Burden of concomitant asthma and COPD in a Medicaid population. Chest 2008; 134:14-19.
28. Soriano JB, Davis KJ, Coleman B, et al. The proportional Venn diagram of obstructive lung disease. Chest 2003; 124:474-481.
29. de Marco R, PesceG, Marcon A, et al. The coexistence of asthma and chronic obstructive pulmonary disease (COPD): prevalence and risk factors in young, middle-aged and elderly people from the general population. PLoS One 2013; 8:e62985.
30. Marsh SE, Travers J, Weatherall M, et al. Proportional classifications of COPD phenotypes. Thorax 2008; 63:761-767.
31. Rhee CK, Yoon HK, Yoo KH, et al. Medical utilization and cost in patients with overlap syndrome of chronic obstructive pulmonary disease and asthma. COPD 2014; 11:163-170.
32. Pleasants RA, Ohar JA, Croft JB, et al. Chronic obstructive pulmonary disease and asthma: patient characteristics and health impairment. COPD 2014; 11:256-266.
33. Soler-Cataluña JJ, Cosio B, Izquierdo JL, et al. Consensus document on the overlap phenotype COPD-asthma in COPD. Arch Bronconeumol 2012; 48:331-337.
34. Izquierdo-Alonso JL, Rodriguez-Gonzá lezmoro JM, de Lucas-Ramos P, et al. Prevalence and characteristics of three clinical phenotypes of chronic obstructive pulmonary disease (COPD). Respir Med 2013; 107:724-731.
35. Golpe R, Sanjuán López P, Cano Jiménez E, et al. Distribution of clinical phenotypes in patients with chronic obstructive pulmonary disease caused by biomass and tobacco smoke. Arch Bronconeumol 2014; 50:318-324.
36. Magnussen H, Bugnas B, van Noord J, et al. Improvements with tiotropium in COPD patients with concomitant asthma. Respir Med 2008; 102:50-56.
37. Chanez P, Vignola AM, O'Shaugnessy T, et al. Costicosteroid reversibility in COPD is related to features of asthma. Am J Respir Care Med 1997; 155:1529-1534.
38. Brightling CE, Monteiro W, Ward R, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: A randomised controlled trial. Lancet 2000; 356:1480-1485.
39. Siva R, Green RH, Brightling CE, et al. Eosinophilic airway inflammation and exacerbations of COPD: A randomised controlled trial. Eur Respir J 2007; 29:906-913.
40. McDonald V, Higgins I, Wood L, Gibson P. Multidimensional assessment and tailored interventions for COPD: respiratory utopia or common sense? Thorax 2013; 68:691-694.
41. Barrecheguren M, Miravitlles M. Asthma-COPD overlap syndrome from a COPD perspective. Eur Respir News 2013; 21:100-107.
42. Nagai A, Aizawa H, Aoshiba K, et al. Guidelines for the diagnosis and treatment of COPD. 3rd ed. The Japanese Respiratory Society. Medical Review Co. Ltd. Tokyo, Japan; 2009.
43. Miravitlles M, Soler-Cataluña JJ, Calle M, et al. Spanish guideline for COPD (GesEPOC) update. Arch Bronconeumol 2014; 50 (Suppl 1):1-16.
44. Kovizek V, Chlumsky J, Zindr V, et al. Chronic obstructive pulmonary disease: official diagnosis and treatment guidelines Biomed of the Czech Pneumological and Phthisiological society: A novel phenotypic approach to COPD with patient oriented care. Pap Med Fac Univ Palacky Olomouc Czech Repub 2013; 157:189-201.
45. Miravitlles M, Soler-Cataluña JJ, Calle M, Soriano J. Treatment of COPD by clinical phenotypes. Putting old evidence into clinical practice. Eur Respir J 2013; 41:1252-1256.